{
    "nctId": "NCT01038466",
    "briefTitle": "Observation Only Study Involving Participants Enrolled in the CHAT Trial",
    "officialTitle": "Follow-Up Observational Study In CHAT Trial Participants With Advanced And/Or Metastatic Breast Cancers That Overexpress HER2, Who Were Randomised To Receive Trastuzumab And Docetaxel With Or Without Capecitabine",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 222,
    "primaryOutcomeMeasure": "The primary endpoints are Time-to-Progression and Overall Survival in the two treatment arms of the CHAT study.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* CHAT trial participants whose data was used in the final data analysis for the CHAT study\n\nExclusion Criteria:\n\n* Any patients who have withdrawn consent to the CHAT study",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}